HP and inflammatory bowel disease: Although robust clinical data on specific microbial alterations and validated biomarkers remain limited, current findings suggest a meaningful correlation between IBD activity, cardiovascular risk, and emerging markers, including zonulin, SCFAs, calprotectin, and C-reactive protein (CRP).